“…(±)-4-Methyl-N-(2-phenyl-2-(prop-2-yn-1-yloxy)ethyl)benzenesulfonamide (3aa). The general method A described above was followed when racemic (±)-2-phenyl-Ntosyl aziridine 1a (50 mg, 0.183 mmol, 1.0 equiv) was treated with propargyl alcohol 2a (21 μL, 0.366 mmol, 2.0 equiv) in the presence of Zn(OTf) 2 (7 mg, 0.018 mmol, 10 mol %) in DCM (44 μL) at RT for 20 min to get 3aa as a white crystalline solid, mp 51−53 °C in 84% (51 mg, 0.154 mmol) yield; R f 0.33 in 20% ethyl acetate in petroleum ether; IR υ max (KBr, cm −1 ) 3280, 2923,2853,2120,1597,1493,1452,1326,1158,1072,814; 1 H NMR (500 MHz, CDCl 3 ) δ 7.72 (d, 2H, J = 8.0 Hz), 7.33−7.31 (m, 3H), 7.29 (d, 2H, J = 8.0 Hz), 7.22− 7.20 (m, 2H), 4.97 (d, 1H, J = 8.6 Hz), 4.55 (dd, 1H, J = 9.7, 4.0 Hz), 4.06 (dd, 1H, J = 16.0, 2.9 Hz), 3.81 (dd, 1H, J = 15.5, 2.3 Hz), 3.25−3.20 (m, 1H), 3.06−3.01 (m, 1H), 2.42− 2.41 (m, 4H); 13 C{ 1 H} NMR (125 MHz, CDCl 3 ) δ 143. 4, 137.3, 136.9, 129.7, 128.8, 128.75, 127.1, 126.8, 79.3, 79.0, 74.9, 55.9, 49.0, 21.5 (±)-5-Methyl-2-phenyl-4-tosyl-3,4-dihydro-2H-1,4oxazine (4aa).…”